Tag: cyclophosphamide

1. Previously untreated chronic lymphocytic leukemia (CLL) patients experienced increased progression-free and overall survival when treated with ibrutinib-rituximab compared to current standard chemoimmunotherapy. 2. Rates of high grade adverse events were similar between treatment groups. Evidence Rating Level: 1 (Excellent)   Study Rundown: CLL is a common hematologic malignancy often treated with a...
1. Previously untreated chronic lymphocytic leukemia (CLL) patients experienced increased progression-free and overall survival when treated with ibrutinib-rituximab compared to current standard chemoimmunotherapy. 2. Rates of high grade adverse events were similar between treatment groups. Evidence Rating Level: 1 (Excellent)   Study Rundown: CLL is a common hematologic malignancy often treated with...
1. Scleroderma patients treated with myeloablative autologous stem-cell transplantation experienced significantly higher rates of disease-free survival at 52 months post-treatment compared to those treated with cyclophosphamide. 2. Treatment-related mortality occurred in some patients treated with stem-cell transplantation. Evidence Rating: 1 (Excellent) Study Rundown: Scleroderma is an autoimmune disorder often resulting in fatal...
1. Multi-target induction therapy for lupus nephritis with mycophenolate mofetil, tacrolimus, and steroids increased remission rates after 24 weeks compared to IV cyclophosphamide and steroids. 2. More patients in the multi-target treatment group dropped out due to adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Current induction therapy regimens for lupus...
Image: PD 1. IV busulfan combined with cyclophosphamide (BuCy) is associated with better leukemia-free and overall survival in acute myeloid leukemia (AML) than total body irradiation (TBI). 2. Improved outcomes and greater ease of administration favor BuCy over Cy/TBI for AML patients in first complete remission (CR) undergoing hematopoietic cell transplantation...
Image: PD/Rituximab (Rituxan, MabThera) 1. At 18 months, patients with ANCA-associated vasculitis treated with one course of rituximab had similar outcomes in terms of inducing remission when compared to patients treated with conventional continuous immunosuppression therapy. 2. The overall rate of adverse events was similar between both groups; however, patients treated with rituximab had lower...